Pharsight

Oseni patents expiration

Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 5 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 5 months from now)

US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone
Jun, 2029

(5 years from now)

Oseni is owned by Takeda Pharms Usa.

Oseni contains Alogliptin Benzoate; Pioglitazone Hydrochloride.

Oseni has a total of 4 drug patents out of which 0 drug patents have expired.

Oseni was authorised for market use on 25 January, 2013.

Oseni is available in tablet;oral dosage forms.

Oseni can be used as method of treating diabetes comprising administering alogliptin, method of treating diabetes comprising administering a compound such as alogliptin.

The generics of Oseni are possible to be released after 04 June, 2029.

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

More Information on Dosage

OSENI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic